Gout is the most common inflammatory arthritis, and almost uniquely among the diseases in this collection it has a mechanism you could explain with a jar of salt water.
Uric acid is the end product of purine metabolism in humans. It circulates as urate, and urate has a solubility limit. Below that limit it stays dissolved. Above it — chronically, for years — it crystallises as monosodium urate in and around joints. Those crystals sit there silently until something mobilises them, at which point the immune system attacks them and produces one of the most painful experiences in medicine: a joint, classically the base of the big toe, that becomes red, swollen and so tender that a bedsheet is unbearable.
That is the whole disease. Keep serum urate below the solubility threshold and the crystals dissolve, the attacks stop, and the deposits disappear. Gout is, in the strict sense, curable.
It is also chronically undertreated. Population data show a rising burden alongside persistently suboptimal management [1] [2] — because the flare is dramatic and the urate level is not, so patients and doctors treat attacks and neglect the number that causes them. That gap between a curable disease and its actual management is what this review is about.
Start here: where the urate comes from
Urate is produced continuously from purine turnover — the body's own cell turnover mostly, diet secondarily — and cleared mainly by the kidney. The kidney's handling is the surprising part: urate is freely filtered and then largely reabsorbed, so the serum level is set by a set of transporters deciding how much to take back [3] [4] [5].
That transporter machinery is why hyperuricaemia is mostly a renal problem rather than a dietary one. Most people with high urate are under-excreters rather than over-producers [6], loss-of-function mutations in the transporter SLC2A9 cause severe renal hypouricaemia [7] [8], and genome-wide association studies of serum urate and of clinically defined gout land repeatedly on transporter genes [9] [10]. Diet matters at the margin — sugar-sweetened soft drinks raise urate measurably [11], weight loss lowers it [12] — and so do drugs, with diuretics and several antihypertensives raising the risk of incident gout [13] [14].
Why crystals hurt is the second half of the mechanism, and it was solved in 2006: monosodium urate crystals activate the NALP3 (NLRP3) inflammasome, driving processing and release of interleukin-1β [15]. That single finding explains the ferocity of the attack, connects gout to a family of inflammasome-driven diseases [16] [17] [18], and predicted a class of treatment.
Pillar 1: measurement and diagnosis
Serum urate, and what it is not
Serum urate is the number that drives everything — and it is not the diagnostic test. In the 2015 ACR/EULAR classification criteria serum urate is one scored laboratory domain among several, while demonstrating crystals is a sufficient criterion that needs no further scoring at all [19] [20]. A urate value on its own neither makes the diagnosis nor excludes it. Treating it as though it did — in either direction — is a recurrent error, and it is a different error from the one that matters most, which is measuring urate correctly and then not acting on it.
The definitive test
Aspirating the joint and finding needle-shaped, negatively birefringent monosodium urate crystals under polarised microscopy is definitive: the presence of MSU crystals in a symptomatic joint or in a tophus was the gold standard against which the classification criteria themselves were built [19]. It also does the thing no blood test can: it distinguishes gout from septic arthritis, which presents identically and is an emergency, and from calcium pyrophosphate deposition (pseudogout), whose crystals are rhomboid and positively birefringent.
In practice most gout is diagnosed clinically, and validated rules exist for primary-care diagnosis without aspiration — one derived against synovial crystals as the reference test, after finding that the positive predictive value of a family physician's unaided diagnosis was only 0.64 [21] [22].
Imaging, which revealed something unexpected
Dual-energy CT distinguishes urate deposits from calcium by their X-ray absorption and can map tophaceous burden non-invasively [23]. Applied to people with asymptomatic hyperuricaemia, it found urate crystal deposition already present in a substantial proportion of them [24] — a finding echoed by ultrasound studies [25]. Deposition precedes symptoms, sometimes by years, and flares appear to be triggered by mobilisation of crystals that were already there rather than by fresh crystallisation. That reframes the first attack: it is not the beginning of the disease, it is the moment an existing deposit became noticeable.
Centerpiece: a simple simulatable model of the threshold
Two published quantities, from two sources, make gout's central logic arithmetic.
The threshold. A review of how hyperuricaemia should be defined proposed greater than 6 mg/dL, on the grounds that the lifelong risk of gout appears to begin at that level — and made the point that this is identical to the minimum target of urate-lowering therapy [25]. The concentration at which urate stops staying dissolved, the concentration that defines the disease, and the concentration treatment aims below are the same concentration. Urate's solubility is a measurable physicochemical property with identified determinants [26], and this is where it bites.
The slope above it. A claims-database cohort of 2,237 elderly patients with gout fitted the relationship between serum urate and flare frequency and reported one continuous coefficient: the average annual number of flares rose by 11.9 percent for each 1 mg/dL increase in serum urate above 6 mg/dL [27].
Compounding that coefficient gives the shape: flare frequency is 1.40 times higher at 9 mg/dL than at the threshold, and 1.96 times higher at 12.
The check turns on the two panels measuring different things, and this is worth being careful about because it would be easy to present them as the same result. The left panel is a rate ratio for the number of flares; the right is an odds ratio for having any flare in a year — 2.1 for the 6–8.99 band and 3.4 above 9, against the below-6 reference [27]. For an outcome as common as a gout flare, an odds ratio must overstate the corresponding rate ratio. The script asserts precisely that: the ratio between the two bands' odds ratios (1.62) exceeds the ratio the continuous coefficient implies between the same bands' flare counts (1.32). They agree in the direction the arithmetic requires, and reading them as interchangeable would be a mistake.
The teaching point is what the threshold licenses. Because this is a solubility problem, driving serum urate below the saturation point does not merely reduce the rate of new crystal formation — it reverses the direction of the equilibrium, so existing crystals dissolve. Tophi shrink. Deposits clear. Attacks stop and do not come back. No other common arthritis has that property: you cannot dissolve rheumatoid pannus or regrow osteoarthritic cartilage by hitting a laboratory target. Gout is treated by treating a number, and the number is the disease.
Three honest limits. The curve is flat below 6 mg/dL because the source's coefficient is defined only above it, not because flare risk is genuinely independent of urate in that range. The cohort was elderly patients identified from claims data, which is not a general gout population. And a coefficient fitted across a cohort describes an average slope; individuals crystallise at different levels, because solubility in tissue depends on temperature, pH and local factors that a serum measurement does not capture.
Pillar 2: treatment
The logic has two tracks that are routinely confused, and confusing them is why gout is undertreated: treating the flare does nothing about the disease, and treating the disease does nothing about the flare in progress.
The acute flare
NSAIDs, colchicine and corticosteroids are all effective, and choice is driven by comorbidity — renal function, cardiovascular disease, diabetes — rather than by efficacy. Colchicine is ancient and has a narrow therapeutic index; low-dose regimens replaced the old escalating ones because the toxicity is dose-related and can be lethal in overdose [28].
IL-1 blockade is the mechanistic treatment, and its existence follows directly from the inflammasome finding [15]. Anakinra was piloted in acute gout [29], canakinumab was trialled in patients with limited treatment options [30], and an oral NLRP3 inhibitor has been tested for flares [31]. These are reserved for patients who cannot take the conventional agents — expensive drugs for a common problem — but they are proof that the pathway was read correctly.
Guidelines set out both tracks [32] [33] [34] [35].
Urate-lowering therapy, which is the actual treatment
Allopurinol inhibits xanthine oxidase, the enzyme producing urate, and is first-line. Its main hazard is a rare severe hypersensitivity syndrome — it has been among the commonest causes of Stevens-Johnson syndrome and toxic epidermal necrolysis [36] [37] — which argues for starting low and titrating, not for avoiding the drug.
Febuxostat is a non-purine xanthine oxidase inhibitor [38] [39]. Its position was complicated by CARES, a trial of 6,190 patients with gout and cardiovascular disease: febuxostat was non-inferior to allopurinol for the primary cardiovascular composite (10.8 versus 10.4 percent, hazard ratio 1.03), but all-cause mortality (hazard ratio 1.22) and cardiovascular mortality (1.34) were higher [40]. Those findings must be read alongside the trial's own limitation — 56.6 percent discontinued the regimen and 45.0 percent discontinued follow-up — but they moved febuxostat to second-line for most patients.
Uricosurics — probenecid, benzbromarone, lesinurad [41] — work at the other end, blocking renal reabsorption, and suit under-excreters who cannot take a xanthine oxidase inhibitor.
The strategy is treat-to-target, and this is the part that gets skipped. The dose is titrated until serum urate is below 6 mg/dL — the same number as the definition of hyperuricaemia [25] — and held there indefinitely. Patients who cannot reach it, or who have tophi and frequent flares despite therapy, are the refractory group [42].
One nuance causes more treatment abandonment than any other. Starting urate-lowering therapy provokes flares, because falling serum urate mobilises existing deposits — the same mechanism that triggers spontaneous attacks. A patient started on allopurinol who has a flare in week three concludes the drug caused their gout and stops it. Prophylaxis with low-dose colchicine or an anti-inflammatory during initiation — studied directly in a pooled analysis of three phase III trials [43] — and explaining in advance why this happens, is the difference between a cured patient and one who abandons treatment.
Comorbidity is not incidental
Gout travels with obesity, hypertension, chronic kidney disease and cardiovascular disease [44] [45]. Whether urate is causal for those outcomes or merely a marker is genuinely unresolved — an umbrella review of observational evidence found the associations widespread but the causal evidence thin [46] — and trials of urate-lowering in chronic kidney disease have been disappointing, with allopurinol failing to slow progression [47] [48] and febuxostat tested in stage 3 disease with asymptomatic hyperuricaemia [49].
The honest position: lower urate to treat gout, which it cures; do not lower it expecting to treat the kidney or the heart.
Pillar 3: what is unresolved
Asymptomatic hyperuricaemia. Crystals are demonstrably deposited in many people who have never had an attack [24] [25]. Whether to treat them is unsettled, and dual-energy CT has made the question sharper rather than answering it.
Whether urate is causal for cardiometabolic disease. The associations are consistent [46] [45]; the interventional evidence does not support treating urate to modify them [47] [48].
The colchicine story is running the other way. Low-dose colchicine reduced cardiovascular events after myocardial infarction [50] and in stable coronary disease [51] — an anti-inflammatory borrowed from gout finding a second life in cardiology, and further evidence that the inflammasome pathway matters beyond the joint.
Closing the treatment gap. The most striking fact in this review is not scientific. A curable disease with a cheap generic first-line drug and an unambiguous laboratory target remains poorly controlled at population level [1] [2]. That is an implementation failure, and it is the largest available gain.
Dig deeper in lmmol
Gout is a renal disease presenting as arthritis: serum urate is set by tubular reabsorption, so kidney function and urate are inseparable — see chronic kidney disease, where the disappointing urate-lowering trials also live [47] [48]. It sits squarely in the cardiometabolic cluster alongside obesity, hypertension — where several antihypertensives raise gout risk [14] [13] — and type 2 diabetes and glycemic control, with the causal direction unresolved [46]. Against rheumatoid arthritis and psoriasis the contrast is instructive: those are immune diseases treated by suppressing immunity indefinitely, while gout is an immune response to a chemical problem, and removing the chemical removes the disease — which is why gout is curable and they are not. The IL-1 and inflammasome biology connects to inflammatory bowel disease as another site where the same innate pathway operates [15]. The full collection is at health.